Open access
Open access
Powered by Google Translator Translator

#ASCO22 – Phase II RCT: Ramucirumab and pembrolizumab vs. standard of care in advanced non–small-cell lung cancer previously treated with immunotherapy.

6 Jun, 2022 | 11:14h | UTC

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A – Journal of Clinical Oncology

Commentary: New drug combination lengthened survival for some with lung cancer – SWOG Cancer Research Network

 

Commentary on Twitter

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.